<DOC>
	<DOCNO>NCT02791230</DOCNO>
	<brief_summary>Phase 3 extension study evaluate safety oral daily dose 20 mg 80 mg tafamidis meglumine subject either transthyretin genetic variant wild-type transthyretin result amyloid cardiomyopathy</brief_summary>
	<brief_title>Long-term Safety Tafamidis Subjects With Transthyretin Cardiomyopathy</brief_title>
	<detailed_description>Global , Phase 3 , double-blind , randomize , long-term extension study evaluate safety oral daily dose 20 mg 80 mg tafamidis meglumine subject transthyretin cardiomyopathy ( TTR-CM ) , complete 30 month study treatment Pfizer protocol B3461028 , 60 month local access tafamidis TTR-CM via prescription , whichever occur first</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Completion 30 month study treatment Pfizer Protocol B3461028 Liver and/or heart transplant , implanted cardiac mechanical assist device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>amyloid</keyword>
	<keyword>transthyretin</keyword>
	<keyword>TTR</keyword>
</DOC>